Monoclonal antibodies (mAb) are studied by the 4 teams of the GICC (EA7501 University of Tours): Frame, PATCH, LNOx and IMT. MAbs have taken a major role in the treatment of cancers or chronic inflammatory diseases. Most mAbs on the market are unconjugated (nus) and act by neutralising the pathogenic effects of an antigen (due to the binding of the mAb on it) and/or by the action of molecular or cellular effectors recruited by mAb. Technological developments are now making it possible to build new structures, the ADCs (antibody-drug conjugate), based on mAbs then used as targeting agents. It is possible to couple small active molecules to a mAb by a linker designed to release the active product under certain pathological conditions. This arm is itself bound to a conjugation head that connects to the mAb. Four ADCs based on the principle of release of a cytotoxic agent into cancer cells after fixation and internalisation of CDA are now used in cancer. Unit chemists (IMT) have the know-how for the design and modular construction of original ADC (all key elements of the CDA are judiciously interchangeable: mAb, catching technique, hydrophobicity and linker length, the release system of the active substance and its nature). Bioconjugation will be used...